Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities a six-year follow-up study

1992 ◽  
Vol 11 (4) ◽  
pp. 536-541 ◽  
Author(s):  
P. Zufferey ◽  
M. Depairon ◽  
A. -M. Chamot ◽  
M. Monti
Keyword(s):  
Raynaud’S Phenomenon ◽  
Prognostic Significance ◽  
Raynaud's Phenomenon ◽  
Capillary Microscopy ◽  
Follow Up Study ◽  
Scleroderma Pattern

scholarly journals THU0357 NAILFOLD CAPILLARY MICROSCOPY HAS LIMITED PROGNOSTIC VALUE IN PREDICTING FUTURE DEVELOPMENT OF CONNECTIVE TISSUE DISEASE IN CHILDREN WITH RAYNAUD’S PHENOMENON.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 410.2-410
Author(s):  
G. Van der Kamp ◽  
D. J. Mulder ◽  
A. Van Roon ◽  
A. Van Roon ◽  
A. Van Gessel ◽  
...  
Keyword(s):  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Prognostic Value ◽  
Raynaud’S Phenomenon ◽  
Raynaud's Phenomenon ◽  
Multivariate Logistic Regression Model ◽  
Multivariate Logistic Regression ◽  
Capillary Microscopy ◽  
Follow Up Study

Background:For adults with Raynaud’s phenomenon (RP), nailfold capillary microscopy (NCM) is established to be an effective method for differentiating between PRP and SRP (1,2). Although Raynaud’s phenomenon (RP) is very common in childhood, studies on diagnostic methods to differentiate between primary RP (PRP) and secondary RP (SRP) at a young age are scarce (3,4).Objectives:The general aim of this study was to determine the prognostic value of nailfold capillary microscopy (NCM) in addition to antinuclear antibodies (ANAs) for later development of connective tissue diseases (CTD) in children with RP.Methods:This was a case-control study, in which 83 patients diagnosed with RP and having undergone NCM in childhood were retrospectively included. Based on whether they were diagnosed with a connective tissue disease (CTD) during follow-up, they were classified as PRP or SRP. PRP and SRP patients were compared on demographics, NCM and ANA positivity. Variables associated with SRP were included in a multivariate logistic regression model. Predictive values were calculated for NCM, ANA positivity and the combination of NCM and ANA positivity.Results:At the time of the baseline NCM, the mean age of the RP patients was 15.4±2.3 years. Averagely 6.4±3.2 years after the baseline NCM, 65 of the 83 patients were classified as PRP and 18 as SRP. The most common CTDs were MCTD and undifferentiated CTD. ANA positivity was associated with SRP (p<0.001). Of the NCM parameters, only capillary loss was associated with SRP (p=0.01). Abnormal numbers of dilated capillaries, giant capillaries and haemorrhages were not significantly associated with SRP. In a multivariate logistic regression model, only ANA positivity was predictive for SRP (OR 11.19, CI 3.07-40.79). ANA alone had a sensitivity of 66.7% and a specificity of 85.9% for SRP. ANA combined with capillary loss had a sensitivity of 33.3% and a specificity of 96.8%.Conclusion:This study demonstrates that childhood RP is primary in most cases. Whereas RP in adulthood is most strongly associated with SSc, children with RP seem to be at risk of developing other CTDs with less apparent NCM abnormalities. Dilated capillaries, giant capillaries and haemorrhages on NCM are not associated with the spectrum of CTDs that children are at risk for, and do not differentiate between primary and secondary RP. Although capillary loss on NCM is associated with SRP, capillary loss may add little to the predictive value of serology. To clarify which NCM parameters are helpful for early detection of SSc-like CTDs, additional research is required.References:[1]Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58(12):3902–12.[2]Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM, Vujasinovic Stupar NZ, Stanisavljevic DM. Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud’s phenomenon. Rheumatol Int. 2012;32(10):3039–45.[3]Jones GT, Herrick AL, Woodham SE, Baildam EM, Macfarlane GJ, Silman AJ. Occurrence of Raynaud’s phenomenon in children ages 12-15 years: Prevalence and association with other common symptoms. Arthritis Rheum. 2003;48(12):3518–21.[4]Pavlov-Dolijanović S, Damjanov N, Ostojić P, Sušić G, Stojanović R, Gacić D, et al. The prognostic value of nailfold capillary changes for the development of connective tissue disease in children and adolescents with primary Raynaud phenomenon: A follow-up study of 250 patients. Pediatr Dermatol. 2006;23(5):437–42.Disclosure of Interests:None declared

scholarly journals Botulinum toxin type A in the treatment of Raynaud's phenomenon: A three-year follow-up study

2018 ◽  
Vol 5 (4) ◽  
pp. 224-229 ◽  
Author(s):  
Susana Medina ◽  
◽  
Alba Gómez-Zubiaur ◽  
Nuria Valdeolivas-Casillas ◽  
Isabel Polo-Rodríguez ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Raynaud’S Phenomenon ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Raynaud's Phenomenon ◽  
Follow Up Study

scholarly journals POS0850 NAILFOLD CAPILLARY DILATIONS IN RAYNAUD’S PHENOMENON: QUANTIFYING A PREDICTIVE THRESHOLD FOR THE ‘SCLERODERMA PATTERN’

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 679-679
Author(s):  
G. Pacini ◽  
M. Pendolino ◽  
C. Pizzorni ◽  
E. Gotelli ◽  
A. Sulli ◽  
...  
Keyword(s):  
Raynaud’S Phenomenon ◽  
Connective Tissue Diseases ◽  
Average Diameter ◽  
Raynaud's Phenomenon ◽  
Clinical Onset ◽  
Primary Raynaud’S Phenomenon ◽  
Venous Diameter ◽  
Pattern Development ◽  
Scleroderma Pattern

Background:Non-specific abnormalities could be detected by nailfold videocapillaroscopy (NVC) in subject with primary Raynaud’s Phenomenon (RP) several years before the clinical onset of connective tissue diseases (CTD)s [1]. Previous findings from our group proved that ≤30 μm capillary dilations in RP patients have a negative predictive value for developing the ‘scleroderma pattern’ during follow-up [2].Objectives:To investigate the role of NVC >30 μm capillary dilations as positive predictive factors of the ‘scleroderma pattern’ in RP patients later developing systemic sclerosis (SSc)-related RP.Methods:A 10-year retrospective NVC-based investigation evaluated the dataset of sequential NVCs of 18 RP patients later developing SSc (cases) and 19 sex- and age-matched RP patients later developing other CTDs (controls). Both cases and controls had ≥1 NVC performed before the ‘scleroderma pattern’/CTD diagnosis (basal NVC) showing >30 μm dilated capillaries. Each NVC was qualitatively and semi-quantitatively assessed, recording number of total capillaries, number and average/site-specific diameters (arterial, apical, venous) of >30 μm dilated capillaries [3]. Statistical analysis was performed to stratify the risk of developing the ‘scleroderma pattern’.Results:Significant differences of capillary diameters were observed between cases and controls both at basal NVC and during follow-up (p<0.001). The proportion of >30 μm dilated capillaries in basal NVC was the strongest predictor of ‘scleroderma pattern’ in a median 3-year time, with a 27% cut-off (PPV 0.79, 95%CI 0.54,0.94; p<0.001). Additional “Higher risk” NVC hallmarks for ‘scleroderma pattern’ development were apical diameter >40 μm (p<0.001), venous diameter >25 µm (p<0.05) and average diameter ≥35 µm (p<0.005). Conversely, CTDs patients showed a stable NVC ‘non-scleroderma pattern’ over a median 10-year time.Conclusion:This is the first study to show that NVC-detected homogeneous and progressive capillary loop dilations in RP patients significantly contribute to predict the ‘scleroderma pattern’ evolution within a median 3-year time, possibly providing a “very early” window of opportunity in SSc pre-clinical stages.References:[1]Cutolo M et al. Expert Rev Clin Immunol. 2019;15(7):753–64. [2] Trombetta AC et al. J Rheumatol 2016;43:599–606. [3] Smith et al. Autoimmun Rev 2020; 19(3):102458.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document